Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
FibroBiologics has completed manufacturing of a third batch of CYWC628, an allogeneic fibroblast cell therapy for diabetic foot ulcers, positioning the company to complete its Phase 1/2 trial with interim efficacy data expected in Q3 2026. The therapy targets a major complication of diabetes where conventional wound healing approaches often fail, addressing both tissue regeneration and the chronic inflammatory environment that impairs healing in diabetic patients.
Insilico Medicine projects revenue growth exceeding 270% to $102.5–$106.5 million by mid-2026, driven by expanding pharmaceutical partnerships and AI platform capabilities. This trajectory reflects accelerating commercial validation of generative AI for drug discovery and development—a structural shift in how compounds are identified, optimized, and brought to clinical stages.
Mitochondrial double-stranded RNA accumulates in the brain after midlife, with levels further elevated in Alzheimer's disease where they correlate with cognitive decline. This accumulation reflects disrupted RNA processing machinery and triggers chronic inflammatory signaling, establishing mitochondrial RNA homeostasis as a measurable driver of age-related neurodegeneration.
Pemvidutide, an investigational dual-pathway therapy, demonstrates sustained metabolic improvements across liver function, lipid profiles, and cardiovascular risk markers in a 48-week Phase 2b trial. The data suggest a mechanistic advantage over single-pathway GLP-1 agents by addressing the interconnected metabolic dysfunction underlying fatty liver disease and cardiovascular risk.
Traditional risk factors—age, sex, smoking, alcohol consumption, waist-to-hip ratio, and BMI—predict chronic disease incidence more accurately than epigenetic clocks in middle-aged adults over 7–9 years. This finding challenges the clinical utility of epigenetic aging biomarkers without demonstrated incremental value over conventional assessment.
Haut.AI has launched an AI-powered platform that analyzes skin across the entire body—not just the face—to provide quantitative measurements and personalized product recommendations. The technology was trained on over 100,000 skin images across all skin types and validated for clinical accuracy, addressing a market gap where 80% of consumers report pressure to maintain healthy-looking skin.
Alterity Therapeutics received FDA alignment on a registrational pathway for ATH434 in multiple system atrophy, with a single pivotal Phase 3 trial expected to support New Drug Application filing. The drug targets iron accumulation and alpha-synuclein pathology, with enrollment planned for late 2026.
DiamiR Biosciences will present three posters at the 2026 Alzheimer's Association International Conference focused on blood-based biomarkers for cognitive decline detection, including plasma APOE genotyping and circulating microRNA signatures. These biomarkers represent a shift toward non-invasive, early-stage identification of neurodegeneration risk before clinical symptoms manifest.
Theriva Biologics is testing a more frequent dosing schedule of VCN-01, an oncolytic virus therapy, combined with standard chemotherapy in newly diagnosed metastatic pancreatic cancer patients. The Phase 2a trial in Spain aims to establish feasibility and safety of three bimonthly doses, building on prior evidence of improved survival outcomes with the current two-dose regimen.
HRS-7535, an oral GLP-1 receptor agonist, demonstrated 11.1% weight loss at 44 weeks in Phase 3 trials with a favorable safety profile dominated by mild-to-moderate gastrointestinal effects. The drug also showed non-inferiority to dapagliflozin in type 2 diabetes management while producing larger HbA1c reductions, positioning it as an alternative to injectable agents in metabolic disease treatment.
NeuroSense is advancing PrimeC, a dual-mechanism oral therapy targeting neuroinflammation and oxidative stress in ALS, into Phase 3 trials after Phase 2b data demonstrated slowed disease progression and survival benefit. The compound addresses multiple pathological drivers simultaneously rather than targeting single endpoints, representing a shift in how neurodegenerative disease progression is being conceptualized and treated.
Valiltramiprosate, an oral agent from Alzheon, demonstrates neurovascular protection and preservation of hippocampal structure in extended analyses of phase 3 and biomarker studies, with clinically meaningful cognitive benefits observed in mild cognitive impairment subgroups despite the primary endpoint not being met. The data suggest potential utility as maintenance therapy following anti-amyloid interventions, particularly for apoE4 carriers at elevated risk for cerebral amyloid angiopathy.